Structure determination of amyloid oligomers, the pathogenic species in Alzheimer ́s disease using fast MAS NMR and microfluidics

Informations projet

Oligomers-MAS-NMR

N° de convention de subvention: 101038074

DOI

10.3030/101038074

Projet clôturé

Date de signature de la CE 31 Mars 2021

Date de début 1 Decembre 2021

Date de fin 30 Novembre 2023

Financé au titre de

• SPREADING EXCELLENCE AND WIDENING PARTICIPATION

Coût total

€ 140 202,24

Contribution de l’UE

€ 140 202,24

Coordonné par

LATVIJAS ORGANISKAS SINTEZES INSTITUTS
Latvia

Periodic Reporting for period 1 - Oligomers-MAS-NMR (Structure determination of amyloid oligomers, the pathogenic species in Alzheimer ́s disease using fast MAS NMR and microfluidics)

Période du rapport: 2021-12-01 au 2023-11-30

Résumé du contexte et des objectifs généraux du projet

Neurogenerative diseases (ND) are one of the major threats to an ever-aging society. Despite this, still no efficient drugs or vaccines are available. Previously, several oligomer and fibril forming proteins, where found in the brains of people who suffered from ND. Structural characterization at the atomic level of these aggregated particles would help to push the discovery of drugs and vaccine candidates against ND. Solid-state nuclear magnetic resonance spectroscopy (ssNMR) at magic angle spinning (MAS) has evolved as a powerful tool for structural biology, especially for proteins involved in ND. However, ssNMR still has a limitation of sensitivity and resolution for site-specific studies. During this project we will address this problem by exploring: (I) cell-free synthesis schemes for novel fluorine incorporation into protein aggregates. (II) engineering of microfluidic devices to prepare oligomeric shape particles. III. Fast MAS methods to detect fluorine and proton nucleus. A combination of these methods could help broaden the boundaries of MAS ssNMR spectroscopy to aid in the development of a new type of therapeutics against ND.

Travail effectué depuis le début du projet jusqu’à la fin de la période considérée dans le rapport et principaux résultats atteints jusqu’à présent

We established a cost-efficient cell-free protein synthesis method in incorporate non-canonical fluorinated aliphatic amino acids. For ssNMR spectroscopy we explored in details coherent and incoherent contributions to fluorine line-widths at various MAS rates. At the moment, it was the first detailed research on this topic in the ssNMR community. We acquired a multidimensional ssNMR spectra and conducted chemical shift assignments of protein aggregates, enabling us to determine the secondary structural elements and compare it with the structures obtained by cry electron microscopy. We build a stable microfluidic device using cheap, in-house manufactured components.
The results achieved in this project were presented as oral or poster presentation in local (Riga in Latvia) and international conferences (Tallin in Estonia, Paris in France, IBCG at Boston in USA). These presentations approach a wide variety of scientist in the fields of protein biochemistry, amyloid proteins and ssNMR. This allowed us to establish new scientific collaborations in Europe.
For a general audience we presented our work in "shadowing days" for high-school students and “Researchers' night” at the hosting institute. Additionally lectures about protein biochemistry and ssNMR methods were presented for university students.

Progrès au-delà de l’état des connaissances et impact potentiel prévu (y compris l’impact socio-économique et les conséquences sociétales plus larges du projet jusqu’à présent)

The scientific results achieved in this project showed the new possibilities of MAS ssNMR fluorine and proton detection methods in studying proteins associated with Alzheimer’s and Parkinson’s diseases. Our advances in protein cell-free synthesis have a potential to establish new biotechnological methods for protein engineering with unnatural amino acids. Both ssNMR spectroscopy and cell-free synthesis could be applied to study other challenging and large protein aggregates, uniquely contributing to the development of new therapeutics against ND.

graphical-abstract.png